For accurate detection of all types of genetic aberrations, various technologies are required. By combining information from multiple technologies, researchers can analyse complex samples and get the most complete overview of disease-driving mutations.
OGT offers an integrated portfolio of products providing clinical researchers with the most advanced tools available to study hematological disorders, including CytoCell® fluorescence in-situ hybridization (FISH) probes and myProbes® custom FISH probes, SureSeq™ next generation sequencing (NGS) panels and myPanel™ custom panels, and CytoSure® array products and custom arrays.
Our products are backed by deep technical expertise and dedicated customer support.
The highly targeted SureSeq™ Myeloid MRD Panel enables the detection of 13 key AML MRD-associated biomarkers to provide a more comprehensive picture of the current AML status of your samples. Key targets include very large, ultra-low frequency FLT3-ITDs (even up to 300 bp) that are traditionally challenging to detect. The streamlined, guideline-driven panel content expands on OGT customer’s MRD detection capabilities to deliver a better understanding of the current AML status, and ensures genomic insights are not missed.
View ProductImproving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples. The figure (above) illustrates the panel's uniformity and high depth of coverage, allowing the confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.
View ProductThe PML probe mix, labeled in red, consists of a 151kb probe centromeric to the PML gene and a 174kb probe telomeric to the PML gene.
View ProductThe RARα (RARA) probe mix, labelled in green, consists of a 167kb probe centromeric to the RARA gene, including the CASC3 gene, and a 164kb probe, including the telomeric end of the RARα gene as well as the TOP2A and IGFBP4 genes.
View ProductOGT’s range of CytoSure® Cancer +SNP arrays combine long-oligo probes for superior copy number variant (CNV) detection alongside single nucleotide polymorphism (SNP) probes – which function using OGT proprietary technology – for accurate identification of loss-of-heterozygosity (LOH). The figure (above) shows a schematic of OGT’s unique SNP probe technology, allowing the use of any reference sample with no restriction digest.
View ProductBenefit from OGT’s extensive array design expertise to produce an array matching your precise specifications. These arrays are ideal if you want to know the precise coordinates of an aberration by analyzing specific areas of the genome at high resolution. The figure (above) shows how our custom arrays can be designed in a variety of formats depending on your desired level of focus, with 1, 2, 4, or 8 arrays available per slide to provide the most cost-effective solution for your research.
View Product
Visit International site
Visit USA site
International
